"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Pioglitazone
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
Men and women aged 18-70 with Type 2 diabetes as defined by:
- Fasting plasma glucose > 126 mg/dL at entry
- Or a two-hour OGTT glucose > 200mg/dL
- Or current treatment with one or two oral anti-diabetic drugs, except TZD
- Or currently using insulin
- Fasting plasma glucose < 200mg/dL at entry
- BMI >27.0 and <45.0kg/m2
- Adequate contraception for women (including, but not limited to: oral contraception, hysterectomy, tubal ligation, or post-menopausal as defined by > 6 months without a menstrual cycle and FSH > 40 mIU/ml).
Exclusion Criteria:
- Significant renal, cardiac, liver, lung, or neurological disease (controlled hypertension is acceptable if baseline bp < 140/90 on medications).
- Prior use of other thiazolidinediones (rosiglitazone [AVANDIATM], pioglitazone [ACTOSTM])
- Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc.
- Pregnancy
- Alcohol or other drug abuse
- Unwilling or unable to abstain from caffeine (48h) and tobacco (24h) prior to metabolic rate measurements
- Increased liver function tests at baseline (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal)
- Metal objects that would interfere with the measurement of body composition /MRS such as implanted rods, surgical clips, etc.
- HbA1C of > 10%.
- NYHA class III/IV CHF is an exclusionary cardiac condition.
- history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
- varicose veins
- major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
- cancer (active malignancy with or without concurrent chemotherapy)
- rheumatoid disease
- bypass graft in limb
- known genetic factor (Factor V Leiden, etc) or hypercoagulable state
- diagnosed peripheral arterial or vascular disease, or intermittent claudication
- family history of primary DVT or PE (pulmonary embolism)
- peripheral neuropathy
Sites / Locations
- Pennington Biomedical Research Center
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Change in skeletal muscle mitochondrial number (electron microscopy + qPCR of mtDNA) and mitochondrial gene expression in T2DM patients treated with pioglitazone (vs. placebo)
Secondary Outcome Measures
insulin sensitivity for insulin suppression of free fatty acid and glucose disposal
electron transport chain activity; mitochondrial content by MRS (ATP max)
intra hepatic and intra myocellular lipid by MRS; mitochondrial content by MRS (ATP max) post weight loss period
Full Information
NCT ID
NCT00402012
First Posted
November 17, 2006
Last Updated
December 17, 2015
Sponsor
Pennington Biomedical Research Center
Collaborators
Takeda Pharmaceuticals North America, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00402012
Brief Title
"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
Official Title
Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Pennington Biomedical Research Center
Collaborators
Takeda Pharmaceuticals North America, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is designed to look at the effect of Pioglitazone treatment on the body's ability to burn food in order to produce energy.
Detailed Description
Skeletal muscle mitochondrial defects are a sine qua non of insulin resistance in patients with T2DM. Pioglitazone decreases free fatty acid levels and restores mitochondria number in adipose tissue whereas high fat diet and lipid infusion decreases genes involved in mitochondrial biogenesis. Increased lipid flux from diet or adipose tissue into skeletal muscle might be the cause of decreased mitochondrial biogenesis. The purpose of this study is to determine if 22 weeks treatment with Pioglitazone can increase mitochondrial biogenesis in muscle in 30 uncomplicated T2DM patients that were previously not taking TZD's. This Phase IV, randomized, double-blind, placebo controlled, clinical trial will consist of 3 phases: a screening, a placebo / Pioglitazone phase (12 weeks) and a weight loss period (6-10 weeks). The primary endpoint is to identify the changes in skeletal muscle mitochondria number and gene expression. Secondary endpoints include MRS measured mitochondrial capacity, insulin sensitivity for glucose disposal and insulin suppression of free fatty acids, electron transport chain activity, mitochondrial content and intra hepatic and intra myocellular lipid. Metformin and Sulfonylurea will be used as standardized oral therapy to maintain HbA1C < 7.0. After completing the protocol, patients will be offered a very low calorie liquid diet (800kcal/d) to assist them in losing weight. During this period they will continue on their previously randomized treatment. When patients lose 10% of their body weight, patients will be switched to a weight maintenance diet (meal replacement with 1 can of glucerna at breakfast and lunch with a "healthy" dinner) for 10 days. MRS measured mitochondrial capacity will again be determined to see if weight loss + pioglitazone has more effect on mitochondrial function than pioglitazone alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
No Intervention
Arm Title
2
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Pioglitazone
Other Intervention Name(s)
TZD
Intervention Description
During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
Primary Outcome Measure Information:
Title
Change in skeletal muscle mitochondrial number (electron microscopy + qPCR of mtDNA) and mitochondrial gene expression in T2DM patients treated with pioglitazone (vs. placebo)
Time Frame
baseline and after intervention
Secondary Outcome Measure Information:
Title
insulin sensitivity for insulin suppression of free fatty acid and glucose disposal
Time Frame
baseline and after intervention
Title
electron transport chain activity; mitochondrial content by MRS (ATP max)
Time Frame
baseline and after intervention
Title
intra hepatic and intra myocellular lipid by MRS; mitochondrial content by MRS (ATP max) post weight loss period
Time Frame
baseline ,after treatment and after weight loss
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women aged 18-70 with Type 2 diabetes as defined by:
Fasting plasma glucose > 126 mg/dL at entry
Or a two-hour OGTT glucose > 200mg/dL
Or current treatment with one or two oral anti-diabetic drugs, except TZD
Or currently using insulin
Fasting plasma glucose < 200mg/dL at entry
BMI >27.0 and <45.0kg/m2
Adequate contraception for women (including, but not limited to: oral contraception, hysterectomy, tubal ligation, or post-menopausal as defined by > 6 months without a menstrual cycle and FSH > 40 mIU/ml).
Exclusion Criteria:
Significant renal, cardiac, liver, lung, or neurological disease (controlled hypertension is acceptable if baseline bp < 140/90 on medications).
Prior use of other thiazolidinediones (rosiglitazone [AVANDIATM], pioglitazone [ACTOSTM])
Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc.
Pregnancy
Alcohol or other drug abuse
Unwilling or unable to abstain from caffeine (48h) and tobacco (24h) prior to metabolic rate measurements
Increased liver function tests at baseline (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal)
Metal objects that would interfere with the measurement of body composition /MRS such as implanted rods, surgical clips, etc.
HbA1C of > 10%.
NYHA class III/IV CHF is an exclusionary cardiac condition.
history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
varicose veins
major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
cancer (active malignancy with or without concurrent chemotherapy)
rheumatoid disease
bypass graft in limb
known genetic factor (Factor V Leiden, etc) or hypercoagulable state
diagnosed peripheral arterial or vascular disease, or intermittent claudication
family history of primary DVT or PE (pulmonary embolism)
peripheral neuropathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven R Smith, M.D.
Organizational Affiliation
Pennington Biomedical Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pennington Biomedical Research Center
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
23818429
Citation
Bajpeyi S, Myrland CK, Covington JD, Obanda D, Cefalu WT, Smith SR, Rustan AC, Ravussin E. Lipid in skeletal muscle myotubes is associated to the donors' insulin sensitivity and physical activity phenotypes. Obesity (Silver Spring). 2014 Feb;22(2):426-34. doi: 10.1002/oby.20556. Epub 2013 Sep 10.
Results Reference
derived
PubMed Identifier
21307136
Citation
Bajpeyi S, Pasarica M, Moro C, Conley K, Jubrias S, Sereda O, Burk DH, Zhang Z, Gupta A, Kjems L, Smith SR. Skeletal muscle mitochondrial capacity and insulin resistance in type 2 diabetes. J Clin Endocrinol Metab. 2011 Apr;96(4):1160-8. doi: 10.1210/jc.2010-1621. Epub 2011 Feb 9.
Results Reference
derived
PubMed Identifier
19887595
Citation
Costford SR, Bajpeyi S, Pasarica M, Albarado DC, Thomas SC, Xie H, Church TS, Jubrias SA, Conley KE, Smith SR. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E117-26. doi: 10.1152/ajpendo.00318.2009. Epub 2009 Nov 3.
Results Reference
derived
Learn more about this trial
"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
We'll reach out to this number within 24 hrs